HC Wainwright & Co. Downgrades Tempest Therapeutics (TPST.US) Rating to Neutral

Summary

HC Wainwright & Co. has downgraded Tempest Therapeutics from a ‘Buy’ to ‘Neutral’, maintaining the target price at $16.00. Tempest Therapeutics is a biotechnology company focused on developing small molecule therapies for cancer treatment by directly killing tumor cells and activating tumor-specific immunity. Its clinical-stage products include TPST-1120 and TPST-1495.Stock Star

Impact Analysis

This event is classified at the company level as it directly pertains to Tempest Therapeutics. The downgrade by HC Wainwright & Co. reflects a change in analyst perspective, potentially indicating concerns about the company’s growth prospects or current valuation.Stock Star Previously, Scotiabank adjusted its rating from ‘Outperform’ to ‘Outperform’ with a decreased target price from $13.00 to $7.00, highlighting further concerns in its valuation Stock Star. The consistent lowering of target prices by different analysts suggests potential challenges or risks facing Tempest Therapeutics. Investors may react by reassessing their positions, leading to possible volatility in TPST stock. Opportunities might arise for value investors if they perceive the stock as oversold, while momentum investors might seek short-term gains through market fluctuations. Risks involve heightened uncertainty about the company’s product pipeline and competitive position in the biotechnology sector.